镰状细胞病患儿的输血治疗
Transfusion Therapy in Children With Sickle Cell Disease.
作者信息
Inati Adlette, Mansour Anthony G, Sabbouh Toni, Amhez Ghid, Hachem Ahmad, Abbas Hussein A
机构信息
*Department of Pediatrics, Lebanese American University and University Medical Center Rizk Hospital, Beirut †School of Medicine, Lebanese American University, Byblos, Lebanon ‡Department of Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX.
出版信息
J Pediatr Hematol Oncol. 2017 Mar;39(2):126-132. doi: 10.1097/MPH.0000000000000645.
Hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation represent the 3 disease-modifying therapies in children with sickle cell disease (SCD). Blood transfusions play an increasingly important role in both prevention and management of SCD complications in this age group. This review will focus on the indications of blood transfusion in children with SCD and modalities of its administration. It will also highlight the complications of this life-saving therapy and ways of optimizing transfusion to minimize its associated risks.
羟基脲、输血和造血干细胞移植是镰状细胞病（SCD）患儿的三种疾病改善疗法。输血在该年龄组SCD并发症的预防和管理中发挥着越来越重要的作用。本综述将重点关注SCD患儿输血的适应证及其给药方式。还将强调这种挽救生命疗法的并发症以及优化输血以尽量减少其相关风险的方法。
Zotero 插件